Silence Therapeutics (SLN)
market vs.
industry GROWTH & VALUE
| Trailing 12m | ||||
| PE Ratio (ttm) | n/a |
|
|
|
| PEG Ratio (ttm) |
|
|
||
| EPS Growth (ttm) | % |
|
|
|
| Dividend Yield (ttm) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 12.2 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Dec | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | TTM | 2012E | 2013E | CAGR / Avg | |
| Revenue | £m | ||||||||||
| Operating Profit | £m | ||||||||||
| Net Profit | £m | ||||||||||
| EPS Reported | p | ||||||||||
| EPS Normalised | p | ||||||||||
| EPS Growth | % | ||||||||||
| PE Ratio | x | ||||||||||
| PEG | x | ||||||||||
| Profitability | |||||||||||
| Operating Margin | % | ||||||||||
| ROA | % | ||||||||||
| ROCE | % | ||||||||||
| ROE | % | ||||||||||
| Cashflow | |||||||||||
| Op. Cashflow ps | p | ||||||||||
| Capex ps | p | ||||||||||
| Free Cashflow ps | p | ||||||||||
| Dividends | |||||||||||
| Dividend ps | p | ||||||||||
| Dividend Growth | % | ||||||||||
| Dividend Yield | % | ||||||||||
| Dividend Cover | x | ||||||||||
| Balance Sheet | |||||||||||
| Cash etc | £m | ||||||||||
| Working Capital | £m | ||||||||||
| Net Fixed Assets | £m | ||||||||||
| Net Debt | £m | ||||||||||
| Book Value | £m | ||||||||||
| Average Shares | m | ||||||||||
| Book Value ps | p | -15.8% | |||||||||
FINANCIAL BRIEF: For the six months ended 30 June 2012, Silence Therapeutics plc revenues decreased 90% to L37K. Net loss increased from L3.4M to L23.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects RNAi Therapeutics segment loss increase from L3M to L22.7M, Unallocated Group segment loss increase of 71% to L858K. more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 30th Jun '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: |
Silence Therapeutics plc (Silence) is a biotechnology research and development company. Silence, along with its subsidiaries, is engaged in research and development of pharmaceutical products. The Company discovers, develops and delivers ribonucleic acid (RNA) interference (RNAi) therapeutics for the treatment of serious diseases. Silence operates two segments: RNAi therapeutics and Immunotherapy. The Company has two licence agreements with partner Quark Pharmaceuticals, for products PF 04523655 and QPI 1002, both of which are in development in two different therapeutic indications. The Company’s product pipeline includes PF 4523655 for diabetic macular edema, PF 4523655 for age related macular degeneration, QPI 1002 for prevention of delayed graft function, QPI 1002 for Acute Kidney Injury, Aut027 for Solid Tumours, and Atu111 for Acute Lung Injury.
Directors: Jerry Randall (Chmn.) , Tim Freeborn (Fin. Dir.) 53,
No. of Employees: 37 No. of Shareholders: n/a
| Last Annual | December 31st, 2011 |
| Last Interim | June 30th, 2012 |
| Shares in Issue | 47,013,554 |
| Free Float | 23.3m (49.5%) |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | FTSE Aim All Share, |
| Exchange |
London Stock Exchange (AIM) |
| Eligible for | an ISA? a SIPP? |
| Address | The Royal Institution of Great Britain,21 Albemarle Street, LONDON, W1S 4BS, United Kingdom |
| Web | http://silence-therapeutics.com/ |
| Phone | +44 20 74916520 |
| Contact | J M Davies (Secy.) |
| Registrar | Capita IRG plc |
| Auditors | KPMG Audit PLC |
| 2nd May | Holding(s) in Company |
| 2nd May | Holding(s) in Company |
| 2nd May | Holding(s) in Company |
| 2nd May | Holding(s) in Company |
| 29th Apr | Result of EGM |
| 10th Apr | Placing and Share Consolidation |
Recent ↓
